Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialResearch in context by Yong Huo, Beijian Chen, Qiufang Lian, Shuqing Wang, Lu Liu, Di Lu, Yanling Qu, Guanzhong Zheng, Lipeng Li, Yuan Ji, Guotian Yin, Wenjun Huang, Ying Xie, Xinchun Yang, Xiufang Gao, Pei An, Fengtai Xue, Haoyu Li, Huan Deng, Li Li, Lijuan Pei, Lei Qian

Connect to this object online.